GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on...
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been awarded the...
— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq:...
Innovative approach accelerates new product development and testing SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a...
Enter your information and we will be in touch with you.
News Sign Up
Sign up to receive news notifications.
Connect With a Rep
Enter your information and we will be in touch with you.
Learn More Today
Fill out the form below for more information.
Webinar Signup
Sign up to receive webinar notifications.
We use cookies to ensure that we give you the best experience on our website. More information about our site Terms of Use and Privacy Policy provide additional details. Continue on to our site only if you agree with these policies.
